CD19 and acute lymphoblastic leukemia: Recently, the U.S. Food and Drug Administration (FDA) approved CAR T cell therapies targeting CD-19 as the tumor antigen: tisagenlecleucel for recurrent pediatric acute lymphoblastic leukemia (ALL) [7] and r/r large B cell lymphoma [8, 9] and axicabtagene ciloleucel for r/r large B cell lymphoma [10, 11].